Last reviewed · How we verify
NCT06946498: FLAT
First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.
NA trial testing Local Anesthesia Thoracoscopy in Suspected Malignant Lung Neoplasm in 100 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | National and Kapodistrian University of Athens |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 23 May 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Local Anesthesia Thoracoscopy
- Pleuroscopy with Rigid Thoracoscope and Forceps biopsies
Conditions studied
- Suspected Malignant Lung Neoplasm — all drugs for Suspected Malignant Lung Neoplasm →
- Pleural Effusion — all drugs for Pleural Effusion →
- Pleural Effusion, Malignant — all drugs for Pleural Effusion, Malignant →
- Mesothelioma, Malignant — all drugs for Mesothelioma, Malignant →
Sponsor
National and Kapodistrian University of Athens
Who can join
Adults 18 to 90, any sex, with Suspected Malignant Lung Neoplasm or Pleural Effusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non randomized study with two groups. The study group includes patients with suspected malignant pleural effusion, in whom the investigation of pleural effusion begins directly with pleural biopsy by Local Anesthesia Thoracoscopy (LAT). The Control Group includes patients who come to the same hospital and are treated with the Standard of Care (SOC) strategies were used. Efficacy of LAT, Sensitivity, Hospitalization, time to diagnosis and general safety and comfort of the groups' subjects will be assessed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Aurora kinases signaling in cancer: from molecular perception to targeted therapies.
Vats P, Saini C, Baweja B, Srivastava SK, et al · · 2025 · cited 6× · PMID 40533769 · DOI 10.1186/s12943-025-02353-3
Verify or expand the search:
- PubMed search for NCT06946498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National and Kapodistrian University of Athens trials
Trials by the same sponsor.
- NCT07295964 — Accuracy of Intraoral Scan Post-processing Methods: A Clinical Trial · NA · not yet recruiting
- NCT07351981 — TcPRF for Knee Osteoarthritis · NA · enrolling by invitation
- NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
- NCT07295899 — Assessing the Influence of Implant Scanning Techniques on the Accuracy of Maxillary Complete-Arch Digital Scans for Impl · not yet recruiting
- NCT06903130 — Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sN · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06946498 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National and Kapodistrian University of Athens
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06946498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing